Verrica Pharmaceuticals (NASDAQ:VRCA) Earns "Neutral" Rating from HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report)'s stock had its "neutral" rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Verrica Pharmaceuticals' Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.18 EPS.

Separately, Needham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $9.50.

Verrica Pharmaceuticals Stock Up 10.0 %

NASDAQ:VRCA traded up $0.04 on Tuesday, hitting $0.48. The stock had a trading volume of 186,265 shares, compared to its average volume of 578,010. The business's 50-day simple moving average is $0.60 and its two-hundred day simple moving average is $0.86. Verrica Pharmaceuticals has a 52-week low of $0.38 and a 52-week high of $11.41. The stock has a market cap of $44.42 million, a price-to-earnings ratio of -0.26 and a beta of 1.68.

Remove Ads

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. The company had revenue of $0.34 million for the quarter, compared to analysts' expectations of $1.30 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. As a group, equities research analysts anticipate that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of large investors have recently made changes to their positions in VRCA. Verition Fund Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the third quarter valued at $89,000. State Street Corp boosted its stake in Verrica Pharmaceuticals by 13.5% in the third quarter. State Street Corp now owns 512,821 shares of the company's stock valued at $744,000 after acquiring an additional 61,041 shares in the last quarter. Jane Street Group LLC grew its stake in Verrica Pharmaceuticals by 106.5% during the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company's stock worth $101,000 after buying an additional 36,028 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the third quarter worth about $335,000. Finally, Barclays PLC increased its stake in Verrica Pharmaceuticals by 404.6% during the 3rd quarter. Barclays PLC now owns 31,341 shares of the company's stock valued at $45,000 after purchasing an additional 25,130 shares in the last quarter. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.